Myelin Protein Zero-Like 2 (MPZL2, also known as EVA1) is an emerging cell adhesion molecule belonging to the immunoglobulin superfamily. Primarily recognized for its physiological role in thymus development and epithelial cell cohesion, MPZL2 is increasingly implicated in solid tumor progression, metastasis, and tissue-specific pathologies. As a single-pass Type I membrane protein, MPZL2 represents a highly druggable target for novel monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and cell therapies targeting epithelial-derived malignancies.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MPZL2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Recombinant Human MPZL2 (ECD-Fc Fusion) High purity (>95%), Endotoxin controlled (<1.0 EU/μg), HEK293 expressed for native glycosylation. Sequence Verified. |
View MPZL2 Products |
| Gene Delivery | MPZL2 Lentivirus Premade Particles Full-length human MPZL2 ORF for stable cell line generation and surface expression validation. |
View MPZL2 Products |
| Benchmark Ab | Anti-MPZL2 Recombinant Antibody Recombinant positive control antibody for binding, flow cytometry, and internalization benchmarking. |
View MPZL2 Products |
| Validator | MPZL2 siRNA Set Target-specific siRNA pool for target knockdown verification and functional specificity assays. |
View MPZL2 Products |
| Related Target A | MPZL1 (Myelin Protein Zero-Like 1) Homologous family member used for specificity screening and counter-selection to prevent off-target toxicity. |
View MPZL1 Products |
| Related Target B | CDH1 (E-Cadherin) Cell junction marker; co-regulated with MPZL2 during epithelial-mesenchymal transition (EMT) and metastasis. |
View CDH1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species ortholog evaluation | Human, mouse, and cynomolgus MPZL2 ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Subfamily counter screening | Homolog panels (including MPZL1 and MPZ) strictly verified by mass spectrometry to guarantee sequence identity. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies available as reference standards. |
| False Positives in Binding | Validated siRNA sets included to confirm target knockdown in cell-based assays. |
Live MPZL2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of MPZL2 is transitioning from basic oncology validation to active drug discovery. Because MPZL2 is overexpressed in several high-prevalence epithelial cancers (including breast, ovarian, and pancreatic cancers) while maintaining restricted expression in healthy adult tissues, it is highly attractive for targeted biologics. The next wave of R&D is focused on capitalizing on its rapid internalization dynamics to develop next-generation antibody-drug conjugates (ADCs) capable of bypassing traditional drug resistance mechanisms.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADCs) | Biotech Startups, Academic Medical Centers | Breast Cancer, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma | Internalization Assay (Requires highly stable, native glycosylated ECD-Fc proteins for kinetic analysis) |
| Monoclonal Antibodies (mAbs) | Oncology-focused Biopharma | Metastatic Solid Tumors | Adhesion Blocking Assays (Requires functional cell lines generated via Lentivirus transduction) |
| Bispecific Antibodies | Immunotherapy Pioneers | Solid Tumors (T-cell engagers) | Selectivity Screening (Requires MPZL2 vs MPZL1 homolog counter-screening panels) |